1. Home
  2. CUE vs FSHP Comparison

CUE vs FSHP Comparison

Compare CUE & FSHP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • FSHP
  • Stock Information
  • Founded
  • CUE 2014
  • FSHP 2018
  • Country
  • CUE United States
  • FSHP United States
  • Employees
  • CUE N/A
  • FSHP N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • FSHP
  • Sector
  • CUE Health Care
  • FSHP
  • Exchange
  • CUE Nasdaq
  • FSHP NYSE
  • Market Cap
  • CUE 48.0M
  • FSHP 92.6M
  • IPO Year
  • CUE 2018
  • FSHP 2024
  • Fundamental
  • Price
  • CUE $0.74
  • FSHP $10.45
  • Analyst Decision
  • CUE Strong Buy
  • FSHP
  • Analyst Count
  • CUE 3
  • FSHP 0
  • Target Price
  • CUE $3.00
  • FSHP N/A
  • AVG Volume (30 Days)
  • CUE 323.3K
  • FSHP 744.0
  • Earning Date
  • CUE 08-13-2025
  • FSHP 01-01-0001
  • Dividend Yield
  • CUE N/A
  • FSHP N/A
  • EPS Growth
  • CUE N/A
  • FSHP N/A
  • EPS
  • CUE N/A
  • FSHP 0.21
  • Revenue
  • CUE $7,991,000.00
  • FSHP N/A
  • Revenue This Year
  • CUE N/A
  • FSHP N/A
  • Revenue Next Year
  • CUE $23.84
  • FSHP N/A
  • P/E Ratio
  • CUE N/A
  • FSHP $49.13
  • Revenue Growth
  • CUE 13.83
  • FSHP N/A
  • 52 Week Low
  • CUE $0.45
  • FSHP $9.99
  • 52 Week High
  • CUE $1.99
  • FSHP $10.48
  • Technical
  • Relative Strength Index (RSI)
  • CUE 51.10
  • FSHP N/A
  • Support Level
  • CUE $0.65
  • FSHP N/A
  • Resistance Level
  • CUE $0.83
  • FSHP N/A
  • Average True Range (ATR)
  • CUE 0.07
  • FSHP 0.00
  • MACD
  • CUE 0.01
  • FSHP 0.00
  • Stochastic Oscillator
  • CUE 30.43
  • FSHP 0.00

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About FSHP FLAG SHIP ACQUISITION CORPORATION

Flag Ship Acquisition Corp is a blank check company formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.

Share on Social Networks: